Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling
- 8 December 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (11) , 2697-2712
Abstract
Background and Purpose: Transglutaminase type 2 (TG2) catalyses formation of ε‐(γ‐glutamyl)‐lysine bonds between proteins, including those of the extracellular matrix (ECM). Elevated extracellular TG2 leads to accelerated ECM deposition and reduced clearance that underlies tissue scarring and fibrosis. Many transglutaminase inhibitors exist and allowed for proof‐of‐concept studies in disease models, but their lack of specificity for the TG2 isoform, and/or poor pharmacokinetic/pharmacodynamic properties have limited their clinical application. We sought to develop a high affinity TG2‐specific antibody against extracellular TG2 activity, with characteristics suitable for therapeutic development.Experimental Approach: Individual human TG2 domains were used to immunize mice and generate hybridomas. Supernatants were screened for inhibition of recombinant human TG2 activity, with TG2 specificity determined by ELISA.Key Results: Thirteen TG2‐specific, hybridoma supernatants inhibited human transamidation activity. Each hybridoma was cloned and the antibody mapped to an epitope in the TG2 core domain, using phage display panning of a TG2 fragment library. Four distinct inhibitory epitopes were determined. The most effective antibodies (AB1, DC1, and BB7) bound to amino acids 313–327 (catalytic core), with an IC50 of approximately 6–7 nM. The antibodies inhibit TG2 in human cells and block ECM accumulation in a primary human proximal tubular epithelial cell model of fibrosis. Only 7 antibodies inhibited rat TG2, all with higher IC50 values.Conclusions and Implications: We identified a preferred inhibitory epitope in human TG2, developed antibodies with required characteristics for clinical development, and established that targeted inhibition of extracellular TG2 transamidation activity is sufficient to modify fibrotic remodelling.Keywords
Funding Information
- UCB Pharma
This publication has 57 references indexed in Scilit:
- Transglutaminase 2 and Its Role in Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2Bioorganic & Medicinal Chemistry Letters, 2011
- Novel therapies for coeliac diseaseJournal of Internal Medicine, 2011
- Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: A potential mechanism of tissue scarringMatrix Biology, 2009
- Tissue Transglutaminase Contributes to Interstitial Renal Fibrosis by Favoring Accumulation of Fibrillar Collagen through TGF-β Activation and Cell InfiltrationThe American Journal of Pathology, 2008
- Fibronectin-Tissue Transglutaminase Matrix Rescues RGD-impaired Cell Adhesion through Syndecan-4 and β1 Integrin Co-signalingJournal of Biological Chemistry, 2008
- Transglutaminase 2 Undergoes a Large Conformational Change upon ActivationPLOS Biology, 2007
- Structure-based design of α-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2Bioorganic & Medicinal Chemistry, 2007
- Transglutaminase 2 inhibitors and their therapeutic role in disease statesPharmacology & Therapeutics, 2007
- Transglutaminases: crosslinking enzymes with pleiotropic functionsNature Reviews Molecular Cell Biology, 2003